A difficult task: The immune system needs to differentiate between the body's own components and foreign agents. It has to fight pathogens and tumor cells, while at the same time refraining from attacking its own organism.
If it mistakenly does target body tissues, this gives rise to so-called autoimmune diseases. These include rheumatism, certain types of diabetes or a skin condition, called psoriasis, to name a few examples.
In order to keep a healthy balance, the immune system needs to control the activity of its numerous components in a very precise way. The regulatory T cells play a major role in this process. The fact that these cells suppress any faulty activation of the immune system has been known for just about ten years. In patients with autoimmune diseases, there is a shortage of these cells while in cancer patients there are often too many of them.
Regulatory T cells: targets for therapies
What do these cells do, how do they control the immune response? Many scientists around the globe would like to find out – this is because the regulatory T cells are interesting targets for new therapies. For instance, there is hope that a better immune response against cancer can be achieved if these cells are temporarily switched off or the symptoms of autoimmune diseases might be alleviated by activating the cells.
Chemical messengers are pumped into "normal" T cells
The characteristics of regulatory T cells are also examined by the study group of Professor Edgar Serfling at the Institute of Pathology of the University of Würzburg. Together with scientists at the University of Mainz, the Würzburg researchers discovered an interesting fact in 2007: Regulatory T cells can communicate with "normal" T cells of the immune system by creating small connecting tunnels between them and pumping the chemical messenger cAMP into the latter.
In response to this, the "normal" T cells stop dividing and halt the production of pro-inflammatory substances. This slows down the activity of the entire immune defense, which is a quite desirable effect in case of an autoimmune disease.
New findings published in PNAS
How exactly do regulatory T cells switch off normal T cells? This is described by Würzburg and Mainz researchers in a current study published in the scientific journal PNAS. In the normal T cells, the transmitted chemical messenger cAMP causes an increased production of a protein that suppresses a large number of genes. "This also includes the NFATc1 gene and consequently the production of pro-inflammatory interleukins is stopped," explains Professor Serfling.
This newly discovered process represents a very important step in the regulation of the immune system. Next, the scientists are going to clarify further molecular details. Their findings might contribute to the future development of new treatments for autoimmune diseases and cancer.
Results as a product of a Collaborative Research Center
The results were obtained within the joint project of the Collaborative Research Centre (CRC) Transregio 52, titled "Transcriptional Programming of Individual T Cell Subsets". The Würzburg researchers Martin Väth and Josef Bodor were the driving forces behind the publication. They were provided assistance at the Institute of Pathology by Friederike Berberich-Siebelt and Edgar Serfling.
Edgar Serfling is the spokesperson for this CRC initiative, in which the Universities of Würzburg and Mainz cooperate with the Charité Universitätsmedizin Berlin. The German Research Foundation has funded the CRC since July 2008 with a grant of about 12 million euros, allocated over an initial period of four years.
"Regulatory T cells facilitate the nuclear accumulation of inducible cAMP early repressor (ICER) and suppress nuclear factor of activated T cells c1 (NFATc1)", Martin Väth, Tea Gogishvilib, Tobias Bopp, Matthias Klein, Friederike Berberich-Siebelt, Stefan Gattenlöhner, Andris Avots, Tim Sparwasser, Nadine Grebe, Edgar Schmitt, Thomas Hünig, Edgar Serfling and Josef Bodor. PNAS, published online on 24 January 2011, doi: 10.1073/pnas.1009463108
Prof. Dr. Edgar Serfling, Institute of Pathology at the University of Würzburg, phone +49 931 201-47431, email@example.com
Robert Emmerich | idw
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
05.12.2016 | Power and Electrical Engineering
05.12.2016 | Materials Sciences
05.12.2016 | Power and Electrical Engineering